Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 184 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Months to 59 Months
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 35 Months
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Nashville, Tennessee
Completed Phase 4 Interventional Accepts healthy volunteers Results available

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781
Conditions
Influenza
Interventions
Fluzone® 2009-2010 Formula, FluMist® 2009-2010 Formula
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Stanford, California
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Influenza
Interventions
Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 48 Months
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Conditions
Influenza
Interventions
2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
5 Years to 8 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Chronic CMV Infection on Influenza Vaccine Responses

NCT02134184
Conditions
Cytomegalovirus Infections, Influenza
Interventions
Fluzone® 2012-2013 Formula NDC No 498281-012-50
Biological
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions
Fluzone Trivalent
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Accepts healthy volunteers

Trivalent rHA Dose Escalation Study in Elderly Subjects

NCT00170443
Conditions
Influenza
Interventions
rHAO Trivalent Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 80 Years
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Houston, Texas
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Conditions
Immunizations, Vaccination, Influenza, School Health
Interventions
School based flu vaccine: Low intensity, School based flu vaccine: High intensity
Behavioral
Lead sponsor
Monroe County Department of Public Health
Other
Eligibility
4 Years to 13 Years
Enrollment
25,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40,805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
188
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Biological · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
3,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more